Floatz logo

Tpst-1120

Metastatic Castration Resistant Prostate Cancer

Tempest TherapeuticsPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Metastatic Castration Resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
Enzalutamide
Jiangsu HengRui Medicine Co., Ltd.
Phase 4BBB
Abiraterone Acetate
Jiangsu HengRui Medicine Co., Ltd.
Phase 3BBB
PREDNISONE TABLETS
Jiangsu HengRui Medicine Co., Ltd.
Phase 3BB
177lu-psma
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2BB
Docetaxel
National Cancer Institute (NCI)
Phase 3BB

View all 39 →

Same molecule, other indications

Tpst-1120 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
56 / 100
View asset →
head and neck squamous cell carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →